Clinuvel Pharmaceuticals Limited


 Clinuvel Pharmaceuticals Limited (ASX:CUV) is a leading and innovative Australian company focused on the development of afamelanotide, its proprietary first-in-class photoprotective drug. Clinuvel has identified five groups of patients with a clinical need for photoprotection. Currently, Clinuvel is in its final stages to complete testing of afamelanotide in Phase II and III trials in Australia and Europe. 


Clinuvel Pharmaceuticals Limited (ASX:CUV) Successful Drug Trial Results For Light Intolerant Shadow Jumpers

🕔7/13/2010 10:21:29 AM 6100

Results released today from a Phase III trial of the drug SCENESSE (R), conducted by Melbourne-based Clinuvel Pharmaceuticals Limited (ASX:CUV) (PINK:CLVLY), have shown that the drug has the ability to reduce and prevent painful phototoxic reactions experienced by patients with erythropoietic protoporphyria (EPP).

Read Full Article

Clinuvel Pharmaceuticals Limited (ASX:CUV) Novel UV Protecting Drug Delivered By The Picogram

🕔7/8/2010 10:36:26 AM 6951

Melbourne's Clinuvel Pharmaceuticals Limited (ASX:CUV) (PINK:CLVLY) today signed with a commercial US partner to manufacture its world's first photoprotective drug, SCENESSE (R), under an exclusive arrangement. Following eight years of development, Clinuvel has selected Surmodics, Inc. (NASDAQ:SRDX), a leading Minnesota-based provider of proprietary drug delivery technologies to the healthcare industry, as its first manufacturing partner.

Read Full Article


  • This Page Viewed: (Last 7 Days: 3) (Last 30 Days: 29) (Since Published: 5590) 

Company Data

  • Level 11, 330 Collins Street
    Melbourne VIC 3000
  • Telephone
  • +61-3-9660-4900 
  • Fax
  • +61-3-9660-4999 
  • Principal Sector
  • Health & Pharm General 
  • Principal Industry
  • Healthcare 
  • Homepage

More News Results

  • 2024/07/05: Notification of cessation of securities - CUV*
  • 2024/07/05: Afamelanotide Assists DNA Repair Response Following UVR*
  • 2024/06/28: CLINUVEL extends Managing Director Employment Agreement*
  • 2024/06/28: Change of Company Secretary*
  • 2024/06/24: SCENESSE European Orphan Drug Designation for VP*
  • 2024/06/18: afamelanotide in fair-skinned Parkinsons patients*
  • 2024/06/11: CLINUVEL Newsletter III - June 2024*
  • 2024/06/05: Update - Notification of buy-back - CUV*
  • 2024/06/03: CLINUVEL withdraws label expansion for adolescent EPP*
  • 2024/05/24: Ceasing to be a substantial holder*
*refer to company website